[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353018-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353018-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","change-in-skeletal-muscle-mass-during-systemic-cancer-treatment-a-systematic-review-and-meta-analysis","Change in Skeletal Muscle Mass During Systemic Cancer Treatment - A Systematic Review and Meta-Analysis","","Loss of skeletal muscle mass (SMM) is frequent during systemic cancer therapy, yet its magnitude and variation across cancer and treatment modalities remain unclear. This systematic review and meta-analysis searched PubMed, Embase, and Web of Science to April 2025 for longitudinal studies and pooled standardized mean changes using random-effects methods. Seventy-eight studies (n=10,502) showed treatment-associated SMM decline, strongest during chemotherapy, with small effect sizes but high heterogeneity, indicating the need for standardized prospective studies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/change-in-skeletal-muscle-mass-during-systemic-cancer-treatment-a-systematic-review-and-meta-analysis/353018/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/change-in-skeletal-muscle-mass-during-systemic-cancer-treatment-a-systematic-review-and-meta-analysis/353018.png","ImageObject",300,407,{"name":42,"@type":43},"McQueen","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the goal of this systematic review and meta-analysis?","Question",{"text":63,"@type":64},"To describe changes in skeletal muscle mass (SMM) during systemic cancer treatment using pooled quantitative estimates.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which studies were included and how was SMM change analyzed?",{"text":68,"@type":64},"Longitudinal studies reporting SMM during chemotherapy and/or immunotherapy (± targeted therapy) were searched through April 2025 and pooled using random-effects meta-analysis with standardized mean changes.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the meta-analysis find about SMM decline across cancers and treatment types?",{"text":72,"@type":64},"Systemic cancer treatment was associated with SMM decline, with the largest declines observed during chemotherapy (± targeted therapy), though effect sizes were generally small and heterogeneity was substantial.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353018,1790460919,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Change in skeletal muscle mass during systemic cancer treatment: a systematic review and meta-analysis  \nLukas Svendsena,b,c , Sandra Jensend , Stine Hansend, Victor Sørensene , Christoffer Johansend,f , Charlotte Suettaf,g , Helle Pappotf,h , Casper Simonseni , Lars Hermann Tangj , Susanne Oksbjerg Daltona,b,c,f , Gunn Ammitzbølla,b,c*  and Bolette Skjødt Rafnd,f*   \nACTA ONCOLOGICA 2026, VOL. 65, 493–510  \n[https://doi.org/10.2340/1651-226X.2026.45726](https://doi.org/10.2340/1651-226X.2026.45726)  \nChange in Skeletal Muscle Mass During Systemic Cancer Treatment: A Systematic Review and Meta-Analysis  \n90  \nREVIEW ARTICLE  \nChange in skeletal muscle mass during systemic cancer treatment: a systematic review and meta-analysis  \nLukas Svendsena,b,c , Sandra Jensend , Stine Hansend, Victor Sørensene , Christoffer Johansend,f , Charlotte Suettaf,g , Helle Pappotf,h , Casper Simonseni , Lars Hermann Tangj , Susanne Oksbjerg Daltona,b,c,f , Gunn Ammitzbølla,b,c*  and Bolette Skjødt Rafnd,f*   \na Department of Clinical Oncology & Palliative Care, Zealand University Hospital, Naestved, Denmark; bDanish Research Center for Equality in Cancer (COMPAS), Naestved, Denmark; cCancer Survivorship, Danish Cancer Institute, Copenhagen, Denmark; dDepartment of Oncology, Danish Cancer Society National Cancer Survivorship and Late Effects Research Center (CASTLE), Rigshospitalet, Copenhagen, Denmark; eMental Health Center Glostrup, Centre for Applied Research in Mental Health Care (CARMEN), University of Copenhagen, Copenhagen, Denmark; fInstitute of Clinical Medicine, Faculty of Health, University of Copenhagen, Copenhagen, Denmark; gGeriatric and Palliative Department, Copenhagen University Hospital, Bispebjerg and Frederiksberg Copenhagen, Denmark; hDepartment of Oncology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark; iCentre for Physical Activity Research, Rigshospitalet, Copenhagen, Denmark; jThe research and implementation unit PROgrez, Department of Physiotherapy and Occupational Therapy, Naestved-Slagelse-Ringsted Hospitals & The Department of Regional Health Research, University of Southern Denmark, Odense, Denmark  \nABSTRACT  \nBackground and purpose: Loss of skeletal muscle mass (SMM) is common during systemic cancer treatment, but the magnitude and variability across cancer and treatment types remain uncertain. We aimed to describe changes in SMM during systemic cancer treatment supported by pooled quantitative estimates. Patients/material and methods: We systematically searched PubMed, Embase, and Web of Science until April 2025 for longitudinal studies reporting SMM during chemotherapy and/or immunotherapy (± targeted therapy) in patients with cancer (PROSPERO CRD42022308388). Standardized mean changes (SMC) were pooled in random-effects meta-analyses using the restricted maximum-likelihood estimator with Hartung– Knapp adjustment. Heterogeneity was assessed using I². Risk of bias was assessed with the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.  \nResults: Seventy-eight studies (n = 10,502; 52% male; median age 64 years [interquartile range, IQR: 34–77]) were included. Meta-analysis across cancers showed an association between systemic cancer treatment and decline in SMM (59 studies; n = 6,373; SMC = −0.24, 95% confidence interval [CI]: −0.29 to −0.20; I² = 92%), corresponding to −5% over a median interval of 90 (IQR: 71–129) days among studies (62%) reporting assessment intervals. Declines were most pronounced during chemotherapy (± targeted therapy).  \nInterpretation: Declines in SMM are frequently observed during systemic cancer treatment, particularly during chemotherapy (± targeted therapy), although effect sizes were generally small per Cohen’s thresholds. However, substantial heterogeneity limits interpretation of a single pooled estimate. Prospective studies with standardized methods are needed to clarify trajectories, mechanisms and clinical implications of SM","cbCaimN1l8Yd95Pt","https://ap.wps.com/l/cbCaimN1l8Yd95Pt","pdf",2605624,"English","# Abstract\n## Background and purpose\n## Patients/material and methods\n## Results\n## Interpretation\n# Introduction\n# Article history and keywords","[{\"question\":\"What was the goal of this systematic review and meta-analysis?\",\"answer\":\"To describe changes in skeletal muscle mass (SMM) during systemic cancer treatment using pooled quantitative estimates.\"},{\"question\":\"Which studies were included and how was SMM change analyzed?\",\"answer\":\"Longitudinal studies reporting SMM during chemotherapy and/or immunotherapy (± targeted therapy) were searched through April 2025 and pooled using random-effects meta-analysis with standardized mean changes.\"},{\"question\":\"What did the meta-analysis find about SMM decline across cancers and treatment types?\",\"answer\":\"Systemic cancer treatment was associated with SMM decline, with the largest declines observed during chemotherapy (± targeted therapy), though effect sizes were generally small and heterogeneity was substantial.\"}]","Change in Skeletal Muscle Mass During Systemic Cancer Treatment - A Systematic Review and Meta-Analysis | PDF",1790102581,48,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4f5de53687ed4c6acdbdcf56dd94e81.webp",983,1280,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba271f64451bfb31d89ef9ee3f2ca658.webp",982,1278,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9d48e00780ae56d1256c08cf02a9812.webp",981,1277,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c54742b0988d14e281275f2d65acc472.webp",980,1276]